Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2025-5497

Published: 2025

Journal Articles

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2025-1944

Published: 2025

Journal Articles

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2025-2744

Published: 2025

Journal Articles

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2025-1565

Published: 2025

Journal Articles

CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2025-4173

Published: 2025

Journal Articles

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Blood (2024) 144 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2024-199287

Published: 2024

Journal Articles

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Blood (2024) 144 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2024-200239

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Blood (2024) 144 (Supplement 1): 2342.

https://doi.org/10.1182/blood-2024-200738

Published: 2024

Journal Articles

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Gloria Iacoboni, Pere Barba, Irma Khvedelidze, Maud Ngoya, Paolo Corradini, Pierre Sesques, Marion Subklewe, Maria Gomes Da Silva, Gilles Crochet, Jarosław Dybko, Izaskun Zeberio, Alejandro Martín García-Sancho, Tom van Meerten, Maeve O'Reilly, Bertram Glass, Ana Maria Sureda Balari, Peter Dreger, Olivier Hermine, Ali Bazarbachi

Blood (2024) 144 (Supplement 1): 3656.

https://doi.org/10.1182/blood-2024-205389

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Vaishali Dulobdas, Amy A Kirkwood, Fabio Serpenti, Brijesh Gautama, Aikaterini Panapoulou, Sumantha Gabriel, Ram Malladi, Jessica Pealing, Denise Bonney, Emma Nicholson, Caroline Besley, Sara Ghorashian, Elizabeth Davies, Jackie Chappell, Anne Black, Tobias Menne, Maeve O'Reilly, Robin Sanderson, Sridhar Chaganti

Blood (2023) 142 (Supplement 1): 495.

https://doi.org/10.1182/blood-2023-178834

Published: 2023

Journal Articles

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Blood (2023) 142 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2023-177715

Published: 2023

Journal Articles

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 1592–1594.

https://doi.org/10.1182/blood-2022-169783

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only